Latest Information Update: 12 May 2004
At a glance
- Originator Roche
- Mechanism of Action Enzyme inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 12 May 2004 Discontinued - Phase-I for Chronic obstructive pulmonary disease (unspecified route)
- 30 Jun 2003 Phase-I clinical trials in Chronic obstructive pulmonary disease (unspecified route)